Minimal residual disease-guided treatment deintensilication for children with Acute Lyrnphoblastic Leukemia: results from the Malaysia-Singapore Acuten Lymphobiastic Leukemia 2003 Study by Yeoh, A.E.J. et al.
A er En.r Jlr Y.oh FaieL Len,JCrs
ae. n Sze Nsr <w.[, r.ng rr.]i alrr.
llaro (lJ,rpa.a. Pol, Ln ran $r.VKow
Y. Kir:i_ ard Th!ar Cr0.U aua r,l'.rq
oc r S.hft of l,/.dc.e llator!
Ur r.rsq o15 ,!a!!re A tn En! Jlh
Yeoh Poh LiTan, and Tr,ar C.or!
Olnh Vla Llrver: t! ah ..c. s ai..e.
C.'tc Jnv.rsrr" ar' lren s ucd cr rsi
lLte Nalona L r!.r!q Hc5p:a, A er En!
juh Y.oi Poi Ln iar .r Tildn ar.rE
O nrl,l.ld:ona Ll r!ere ty aancLr insiiui!
01!nqarcre, Nar.na rnv€ sl! Hla t
srsre,f, A e. Eng 
-Lt Yeolr Cincer
Sce'.e ns1tu€ rlr.tu Jries1,"oi
Srgap.re (!FEn Fornlo! a iarTdL
S.nq Hlspr, Mc Ylre Crc. dnd Ah
lloy I3n K( \'!.m:r s... ah.L.i:
i_l6pIa SnOaDi,e Fan\, Arll. iinr.rety
of Maava Ca,.c.r llcscarcl j5tt!t.iHa.y
Ari n and Lee A Cho...l Ur ve:sr!.t
lr'id:,,? (.:r LlmpJr a.d Fd Pen! Li
5 nt Daby M€d,- C. nrc, SlLrin.r Java
Srbnted []oi.rre: lC 20ll :c..pte!
lrl. ch 20 2012 D!: s.ed .n E n rerrl oi
pI lr .1 e.l..ur ld! org on [1ay 2] 2012
S!pp.r.d by ar.n:! ic.r i,i! Srcap.re
ll:lona M.d.a ucscarch Cor,r. iNitFC/
453if2001, lll!1Fu Nl\,lFiasrrr'lro3/2ur8l
A',STAR r5C9trOLl98, NIVRLICS,1104/
20051, Ch drcf r Crn.er id rlalon an.l
tre V\A Fllndai.. Tlre Lelkerir Tr5!e
Sa.k s supDo.cd Lr Lhe Can..r S.enc.
Altrri !lsio5lrrs ol tEter:5 .o.l .ts
rt rrer.sr..d iutfo'.onrLuc- are
lor.o a! the €nd oi th.:1..
aoricsDord.!;!ir., r\ er Enq J!r f.oil
MD aear,_.r,..t.t F.dal c5 Dvsiorof
Fl.m.I!lgy afd Oncoolly l.la:.na
Ur lers !. lea rh Sr'sler To.rcr B o.r
lF (eri Fdqe Fd S nlarrcre I19229,
c Ta a ef leln@rurj enu sq
O 2Nl2 cr An!rc.i.5-et! 01C r.a
07:2 -83V12,€019 23!4$2! 01.
DO a t2oallao 2al l4a593rl
VOLUME 30 NUMBEF ]9 JULY 1 20]2
JounNer, or Clwrcel Owcor,ocy
Minimal Residual Disease-Guided Treatment
Deintensilication for Children With Acute Lyrnphoblastic
Leukemia: Results From the Malaysia-Singapore Acute
Lymphobiastic Leukemia 2003 Study
AIIett Enu Jtrh yeolt, Htiiq, Ariflin, Elairc Li I eng Chai, C€.;/ir Sze r\-gi, Ku,ot, Yiang Hutk Chan,
KupennPonnudu li, I)dria Aut pLlnd, Poh Lin Tnn, Mci Yoke Chan, Slti q,KctvYinKhuntt,eeNChong,
Ah MoyTan, HaiPcngl.in, and Thttan ChongQuLth
ABSTRACT
Purpose
o rmprove treatment ouicome for ch dhooci acute lymphob asttc eukem a (ALL), we desrgned
the Ma ays a-S ngapore ALL 2003 studv with i.eatment stratif cation based on present ng clln cal
and genetic feairres and minLma residua dsease (lvlRD) eves measu.ed by poymerase chan
reaction target ng a s ngle ant gen receptor gene TearTangement
Patients and Methods
Five hundred ftty-sx paiients receved rskadapted therapy wrth a modfied Berl n Frankturt-
Munster-ALL lrealment. H gh-rsk ALL was defined by MRD > 1 x 10 3 atweek T2 and/or poor
pTedn so one response, BCfi ABL 1 , MLL gere TeaTrangements, hypodiplo d ess than 45 chromo
somes, or nduction fai ure; standard r sk ALL was defined by lvlBD 
= 
I x 10 ' at weeks 5 and
12 and no exiraTnedlr ary:nvoivement or hghtsk teatures intermed ate r sk ALL ncuded al
rema n ng pat enls
Results
Patents who acked hgh-tsk preseitlng featutes (85.7%) received reTrrisson lnduction therapy
w th dexamethasone, v ncTist ne, and asparag nase, w thout anthracyc ines. S x year event-fTee
survrva (EFS) was 80 6% a 3 5%;overa survlva was 88 4% :t 3 1% Standa.d-risk patients {n :
112, 31a/;t received sign i cant y de ntensi|ed subsequenr therapy w thout compronris ng EFS
1932%14.1Vo). H gh r sk patlents (n = 101; 1B%) had rhe wo.st FFS {51 B% ! 10%), EFS was
83 6r/a ! 4.9% n nternned ate risk pat ents {n = 283; 51 %).
Conclusion
O!r resuts denronstrate signfiaant progress oveT pTevoLts tras n the region. Three-drdg
rem ssion nduct oN therapy cornb ned with MRD based r sk slratil cation to dentily poor respond-
ers s an effect ve strategy fof ch dhood ALL.
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rovly discoverecl qenetic and bicrlogic factors are
becoming incre.rsingly nrore inportant.i 7 Early re
\.'Iore than ll00i of childr-en diagnoscd with acute sponse to thcrapy is strongl,v irssociatecl nith risk of
lylt-tphoblastic leukemil (ALl) in developed coun rehpse. lnitial observirtions blsed on morphologic
tries are norv iong term sun'ivors. 
" 
Thi, |j,.rca"ra itssessrncnt oftreatment responscs have been con-
can be attributetl to a combination of 1acto6, in solidated b,v nLrmerous studics performecl during
cludiug increasirgly accurate risk assiginent stritt- thc iast two decitdes. StLldics oftreatn'ient rcsponse
ellics that reduce relapse causcd by ullderlreahrelt meirsured by more scnsitire and objective rnethods
and toxi.ities causcd by ovenreiltmcnt- Holvever, that can detect lcul(cmia cells undetectable b]' nlor
cure ratcs fbr childrer \\'ith ALL trcatcd oubide the phology (ie, minimal residual disease IMRDI) hare
major US and Europcan nrulticertcr sludics havc providetl a rationele lor the incorporation ofitlRl)
laggccl beh in d, pa rticularly in developing countrics. r testinli in risk assignnrent strrteeies.err In patienls
With conteoporaq- chenotherap), lllc prog wilh AI-l-, \{RD cnn be uloiibred b1-florr q'tomet-
lostic strrngth oltraditiooal clinicrl presentiug fea- ricrr or molecular methodsj among the latter, the
tures ofi\Ll is dim inish ing, ufi e reas estabJishecl lncl clinical useliLlness of poh'merase chain reaction
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